Dengue Literature Review

E Protein

5 min read

E Protein

Overview

The envelope (E) protein is the major surface structural protein of dengue virions and the primary target of neutralising antibodies. It mediates two critical steps in viral entry: receptor binding (via domain III) and membrane fusion (via the domain II fusion loop in the acidic endosomal environment). E protein is presented as 90 tightly packed homodimers (180 monomers total) lying flat against the viral lipid bilayer. Most vaccines targeting dengue focus on the E protein as the principal antigen. A six-amino-acid motif in the E protein (WGNGCG, aa 101–106) shares sequence homology with human coagulation factors and has been proposed as a molecular basis for dengue-associated coagulopathy.

Key Points from Literature

Structure and function

  • 90 tightly packed monomers on the viral surface; organised into three domains: DI (central), DII (dimerisation and fusion), DIII (receptor binding)
  • DIII is responsible for binding to host cell receptors; several mutations in DIII affect receptor binding
  • DII fusion loop: the DI-DII hinge is highly flexible; low pH in the endosome causes hinge rearrangement, exposing the fusion loop → interaction with endosomal membrane → viral RNA release into cytoplasm
  • prM/M: newly released virions can be immature (prM-containing, non-infective) or mature (M-containing, infective); some particles are a mix; partially immature particles may or may not be infective (see Guzman2016 - Dengue Infection)

As vaccine antigen

  • Most neutralising antibodies target the E protein; DIII is a major focus for subunit vaccine design (e.g. DIII-Capsid fusion construct by IPK Cuba; 80E truncated recombinant E)
  • Broadly cross-neutralising antibodies targeting quaternary epitopes at the DI-DII hinge region of intact virions provide pan-DENV neutralisation but are a minor fraction of the antibody response
  • CYD-TDV uses the prM and E genes of all four serotypes inserted into the yellow fever 17D backbone; all other chimeric vaccine approaches similarly use E protein as the key antigen (see Guzman2016 - Dengue Infection, CYD-TDV)

Coagulation factor homology (WGNGCG motif)

  • E protein aa 101–106 contains the motif WGNGCG with sequence homology to coagulation factors XI, X, IX, VII, II (thrombin), plasminogen, and tPA
  • Anti-E antibodies bind human plasminogen and inhibit plasmin activity — a direct anti-fibrinolytic mechanism
  • The WGNGCG motif is conserved across haemorrhagic flaviviruses (JEV, WNV, YFV, TBE, OHFV) but absent in HCV; its presence tracks with haemorrhagic phenotype across the genus (see Lin2011 - Molecular Mimicry Virus Host Dengue Pathogenesis)

Longitudinal kinetics — cross-reactive EDI/II IgG rises post-primary infection (Bos2025)

Bos2025 - Longitudinal Antibody Dynamics After Dengue provides domain-resolved longitudinal data on anti-E antibody kinetics in a Nicaraguan pediatric cohort (n=79; DENV-1/DENV-3; <1M, 3M, 6M, 18M post-infection).

PREPRINT — not peer reviewed.

  • Cross-reactive E-protein IgG (XR E-IgG) rises 6–18M post-primary: t½ = −2.13 years (growth trajectory). This finding challenges the classical model that cross-reactive antibodies wane monotonically after primary dengue.
  • Domain specificity is the key driver: Antibodies targeting EDI/II (the dimerisation and fusion interface, site of many cross-reactive epitopes) are responsible for the rising trajectory. Antibodies targeting EDIII (the receptor-binding domain, site of serotype-specific neutralising antibodies) remain flat during this window.
  • Implication for ADE risk: The EDI/II-targeting cross-reactive pool that rises post-primary infection is not enriched for neutralising antibodies — it is the population most likely to bind heterotypic virus without neutralising it, consistent with ADE-mediating antibodies. The ADE risk window may therefore be driven by active accumulation, not passive decay below the neutralisation threshold.
  • Secondary infection kinetics show more compressed, attenuated trajectories at 18M, consistent with rapid recall and contraction in a memory-primed host.

Anti-E is a minority of the structural antibody response — anti-prM dominates

Human monoclonal antibody (hmAb) isolation from 7 DENV-infected Thai donors (3,020 B cell lines screened) found that only ~35% of anti-dengue structural antibodies were anti-E; approximately 60% were anti-prM (see Dejnirattisai2010 - Anti-prM Antibodies Enhance Dengue ADE, n=7 donors, experimental). This contrasts with the prior assumption that anti-E constitutes the primary structural humoral response.

Key distinctions between anti-E and anti-prM in the Dejnirattisai2010 dataset:

  • Serotype specificity: Anti-E hmAbs showed more serotype-restricted binding; anti-prM hmAbs were fully cross-reactive across all four serotypes.
  • Neutralisation: Anti-E hmAbs achieved higher PRNT inhibition, consistent with classical neutralising antibody activity. Anti-prM hmAbs plateaued at 10–60% PRNT and could not achieve complete neutralisation.
  • ADE magnitude: Anti-prM hmAbs mediated up to 10^5-fold enhancement in primary monocytes and DCs — substantially greater than anti-E ADE.

The WGNGCG coagulation factor homology motif resides in domain II of E protein (aa 101–106), meaning it is expressed on mature virions. Anti-E antibodies targeting this region would engage mature, infective particles — distinct from anti-prM, which targets the immature/partially immature fraction.

Contradictions & Debates

  • The relative contribution of anti-E WGNGCG-mediated coagulation interference (Lin2011) vs. direct NS1-thrombin binding (Guzman2016) to the coagulopathy of DHF has not been disentangled in clinical studies.

Sources

Graph View

Backlinks